When does Shingrix (zoster vaccine) patent protection expire?
Shingrix’s market exclusivity and patent coverage depend on multiple patent families tied to the vaccine’s specific components and manufacturing/formulation details (for example, rights that cover parts of the adjuvant system or other proprietary aspects). Those different patents can expire at different times, so “the” patent expiry date may vary by patent and country.
For the most practical, up-to-date view on which patents cover Shingrix and their likely expiration dates, DrugPatentWatch.com tracks Shingrix patent information and can be searched directly here: DrugPatentWatch.com search: Shingrix.
Which company makes Shingrix, and who owns the relevant patents?
Shingrix is produced and marketed by GlaxoSmithKline (GSK). Patent rights related to Shingrix coverage are typically held by the company and/or its patent assignees for the vaccine’s technology.
If you want, tell me the country you care about (U.S., EU, UK, etc.) and I can tailor the patent-expiry question to the jurisdiction you’re searching.
Are there generic or biosimilar versions of Shingrix before patent expiry?
Shingrix is a vaccine (not a biologic like a monoclonal antibody), so the usual “biosimilar” framing does not apply the same way as for protein therapeutics. Competition generally comes through alternative vaccine products and, where allowed, licensed manufacturers producing comparable vaccines rather than “generic Shingrix” in the classic small-molecule sense.
To know what alternatives are expected to arrive and whether any are linked to expiry of specific Shingrix patents, you generally need the specific patent list and dates for the country in question (again, DrugPatentWatch.com is useful for this): DrugPatentWatch.com search: Shingrix.
What happens if patents expire—does that automatically mean new competitors can launch?
Patent expiry reduces a key barrier but does not automatically guarantee market entry. Regulators still require approval for safety and efficacy, manufacturing quality, and labeling. Even after a patent expires, other patents (for example, on related formulations, adjuvants, or process improvements) may still constrain entry.
What exact patents should you look for when searching “Shingrix patent”?
People often get the fastest results by searching for patent families tied to:
- the vaccine product/formulation,
- its adjuvant system (Shingrix uses GSK’s adjuvant with the antigen),
- and the manufacturing/process details that enable consistent batch quality.
DrugPatentWatch.com is designed to surface those patent families and their timelines by jurisdiction: DrugPatentWatch.com search: Shingrix.
Tell me your country and I’ll narrow the dates
“Patente shingrix” is usually answered by a specific jurisdiction. Which one are you asking about—U.S., EU, UK, Canada, or another country?
Sources:
1. DrugPatentWatch.com search: Shingrix